Cubist Pharmaceuticals integrates Reprints Desk's document delivery service and QUOSA's Virtual Library

NewsGuard 100/100 Score

Reprints Desk, Inc., and QUOSA, Inc., today announced that Cubist Pharmaceuticals has become the first shared customer to activate integration between Reprints Desk's STM Document Delivery service with QUOSA's Virtual Library, which facilitates copyright-compliant article archiving and scientific literature re-use. The integrated solution features integration with Rightsphere, the rights advisory and management tool from Copyright Clearance Center (CCC), which already integrates independently with both Reprints Desk and QUOSA.

"The integration of QUOSA's powerful solution for archiving and sharing scientific journal articles with Reprints Desk's ultra-rapid document delivery service was a logical collaboration for delivering the efficiency and compliance benefits we've been seeking to enhance our eLiterature services," said A. Amyas Huston, Senior Manager of Medical Communications at Cubist. "With QUOSA already deployed and Reprints Desk delivery not requiring any platform fees or any IT information technology involvement from Cubist, the implementation within our workflow processes was fast and seamless."

SOURCE Reprints Desk, Inc.

Comments

The opinions expressed here are the views of the writer and do not necessarily reflect the views and opinions of News Medical.
Post a new comment
Post

While we only use edited and approved content for Azthena answers, it may on occasions provide incorrect responses. Please confirm any data provided with the related suppliers or authors. We do not provide medical advice, if you search for medical information you must always consult a medical professional before acting on any information provided.

Your questions, but not your email details will be shared with OpenAI and retained for 30 days in accordance with their privacy principles.

Please do not ask questions that use sensitive or confidential information.

Read the full Terms & Conditions.

You might also like...
New urine-based test improves identification of high-grade prostate cancer